{macro question(showVoteTotal)}
    <div class="poll-question">
      {if keyType == "discussion"}
        <a href="/forums/?plckForumPage=ForumDiscussion&plckDiscussionId=${key}#forumPostTitle_1" title="View discussion">
          ${poll.Question}
        </a>
      {else}
        ${poll.Question}
      {/if}
      {if showVoteTotal}
        <span class="poll-votes">(${poll.TotalVotes} ${"vote"|pluralise:poll.TotalVotes})</span>
      {/if}
    </div>
  {/macro}
  <div class="slResults" {if !noVote}style="display:none;"{/if}>
    ${question(true)}
    <table class="slAnswerStats" cellpadding="0" cellspacing="0" border="0">
      {for answer in poll.Answers}
        <tr class="slAnswerStat slAnswerStat_${answer_index}">
          <td class="slAnswer">${answer.Answer}</td>
          <td class="slAnswerBarCell">
            <div class="slAnswerBar">
              <div class="slAnswerCount">${answer.NumberOfVotes} ${"vote"|pluralise:answer.NumberOfVotes} (${answer.PercentageStr}%)</div>
              <div class="slAnswerBarPercent" style="width: ${answer.Percentage}%;"></div>
            </div>
          </td>
        </tr>
      {/for}
    </table>
    {if !noVote}<div class="results"><a href="javascript:void(0);" class="slVoteLink">Go vote!</a></div>{/if}
  </div>

{if !noVote}
  <div class="slVote">
    <div class="slErrorText">You must select one answer before submitting your vote.</div>
    ${question(false)}
    <table class="slAnswers" cellspacing="0" cellpadding="0" border="0">
      {for answer in poll.Answers}
        {var answerId = poll.PollKey.Key + '.' + answer_index}
        <tr>
          <td class="slAnswerInput">
            <input type="radio" name="answers" value="${answer_index}" id="${answerId}"/>
          </td>
          <td class="slAnswerText">
            <label for="${answerId}">${answer.Answer}</label>
          </td>
        </tr>
      {/for}
    </table>
    <div style="clear: both; margin-left: 8px;">
      <div class="slSendAnswer"><input class="slVoteButton" type="button" value="Vote" /></div>
      <div class="results"><a href="javascript:void(0);" class="slResultsLink">View Results...</a></div>
    </div>
  </div>
  {/if}

What do you think?

To use this site you must have Javascript enabled

doc2doc is a doctors community site with secure doctor forum & doctors social networking. Join for free today to get answers from your peers to your clinical questions

Should We Trust in The Diabetic Drug Industry?

False

Diabetes

Should We Trust in The Diabetic Drug Industry?

Discuss any aspect of type I or type II diabetes mellitus here

"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial" Lancet A

0

Cat:OpenClinicalForum:209c1fee-a6e1-4cf9-9bd5-7d4dd5443e39

Cat:OpenClinicalForum:209c1fee-a6e1-4cf9-9bd5-7d4dd5443e39Discussion:a11ef4f2-18cf-4943-8097-41ec0c07e839

Forums » Open clinical » Diabetes » Should We Trust in The Diabetic Drug Industry?

You must be logged in to contribute. Log in | Register

Forums » Open clinical » Diabetes » Should We Trust in The Diabetic Drug Industry?

Should We Trust in The Diabetic Drug Industry?

posted at 10/8/2012 1:45 PM BST on bmj.com

Joey Rio

Posts: 624
First: 13/4/2011
Last: 15/5/2013

"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial" Lancet August 4th 2012.

Interpretation:

The results of this long-term randomised active-controlled trial advance the clinical evidence and comparative effectiveness bases for treatment options available to patients with type 2 diabetes mellitus. The findings could improve decision making for clinical treatment when metformin alone is insufficient.

Funding:

Boehringer Ingelheim.

Comments:

This trial shows that linagliptin is non-inferior than glimepiride, ie, both lower glucose by about the same amount, and with less risk of hypoglycaemia for linagliptin. Hypoglycaemia can be most influenced by a number of variables beyond classes of drugs, like for example targets for HBA1C. Actually in this trial glimepiride reduced further HBA1C than linaglipitin, but the non-inferiority statistical methodology (trap) showed that it did not happen.

But the most important issues here are:

1. Do we know the long-term Safety of Linaglipitin? No.

2. Do we know the long-term Cardiovascular Benefits or Clinical Harms of Linaglipitin? No.

3. Was this a long-term clinical trial related to a disease that affects patients usually for decades of their lifes? No.

4. Is it ethical not discussing the unresolved Safety and Efficacy isues of this still experimental anti-diabetic drug openly with the patients when prescribing a DPP4 inhibitor?

All Best,

Joey

New post Reply to this post

Re: Should We Trust in The Diabetic Drug Industry?

posted at 10/8/2012 7:06 PM BST on bmj.com

Dr. K. Ashutosh

Posts: 3045
First: 27/3/2012
Last: 20/5/2013

A very important eye opener post!
We should not easily trust in the diabetic drug industry. Most of times the pharmaceutical industries are hiding important clinical aspects in commercial interests.

New post Reply to this post

Forums » Open clinical » Diabetes » Should We Trust in The Diabetic Drug Industry?